U.S. approves $2 million Novartis gene therapy for rare, deadly muscle disorder
By John Miller and Caroline HumerZURICH/NEW YORK, May 24 - Swiss drugmaker Novartis won U.S. approval for its gene therapy Zolgensma for spinal muscular...
By John Miller and Caroline HumerZURICH/NEW YORK, May 24 - Swiss drugmaker Novartis won U.S. approval for its gene therapy Zolgensma for spinal muscular...